Key Considerations
-
Pfizer ranks among the globe’s largest pharmaceutical firms.
-
Historically, the company has excelled at developing new blockbuster medications to replace those that have expired their patent protection.
-
The ongoing challenges from current patent expirations will eventually be addressed.
Pfizer (NYSE: PFE) is currently experiencing a lack of favor among investors. The situation stems from various factors, particularly concerning its drug lineup. With three medications set to lose patent protection in 2027 and 2028, and no immediate replacements, investors are adopting a cautious approach. This leads to the question of whether purchasing now could be advantageous.
Where is Pfizer headed?
Pfizer operates in a highly competitive pharmaceutical landscape. This field is marked by technical challenges and rigorous research and development, along with considerable regulatory obligations. Products also have a limited lifespan before generics can enter the market.
It appears that smaller pharma companies frequently rise and fall. Yet, only a select few have endured the sector’s volatility like Pfizer. Currently, the company boasts a market capitalization of $145 billion, despite a steep 55% drop since its peak in 2021.
A key issue confronting major pharmaceutical corporations, such as Pfizer, is the infamous patent cliff. This term refers to when lucrative blockbuster drugs lose patent protection. Given the substantial investment needed to develop new drugs, firms are granted a limited period of exclusivity to recover costs. However, once patents expire, the profits can sharply decline.
Pfizer is facing three significant patent expirations: the oncology treatment Ibrance will lose protection in 2027, followed by the cardiovascular drugs Eliquis and Vindaquer, which will expire in 2028.
This is common in the pharmaceutical sector.
It’s crucial to remember that patent expirations are a regular occurrence, and Pfizer has historically navigated such challenges successfully. The company can either create new drugs internally or take the route of acquisitions. Recently, Pfizer’s acquisition of Metsala appears to align with managing its impending patent cliff.
This acquisition was motivated by Metsala’s promising drug pipeline for obesity, especially after scrutiny of Pfizer’s own obesity medication. The board of directors is determined to ensure progress for the company, which should encourage long-term investors to adopt a more optimistic view regarding Pfizer’s potential turnaround.
However, there’s an interesting twist to consider. The current decline follows an overly optimistic period during the early days of the pandemic when investor confidence surged due to Pfizer’s vaccine. As the world adjusted to life with COVID-19, share prices fell back, compounded by concerns over the upcoming patent cliffs, now placing stocks below pre-pandemic values.
Given this context, it seems the market’s negativity might be exaggerated. Pfizer’s move into the obesity drug sector reflects a broader industry trend, which could help it stabilize. Historically, the company has consistently demonstrated its ability to innovate and develop new therapies.
Things to consider regarding Pfizer
For many investors, the 6.6% dividend yield might suggest that Pfizer is an appealing option for those seeking dividends. Still, it’s wise to tread carefully. The dividend payout ratio has hovered around 100%, and there have been past instances where dividends were cut following significant acquisitions.
Viewing Pfizer through the lens of a turnaround scenario is perhaps the most prudent approach. If the dividend management remains solid, that’s certainly a plus.
Should you invest $1,000 in Pfizer right now?
Before diving into an investment in Pfizer, consider the following:
According to our analysis at Motley Fool Stock Advisor, other investment options may present more compelling opportunities right now—particularly, some stocks that are not Pfizer but might yield substantial returns over coming years.
For context, think of Netflix, which has seen tremendous growth since being recommended back in 2004, or Nvidia, whose gains in the same period are impressive. It’s clear that diversifying into other options can be strategically beneficial.
In summary, the Stock Advisor’s overall performance has outstripped the S&P 500 significantly, showcasing some success that investors might want to consider as they evaluate Pfizer against other possibilities.
